# Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

> **NCT06834373** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 41 (estimated)

## Conditions studied

- Large B-Cell Lymphoma With IRF4 Rearrangement
- Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
- Recurrent ALK-Positive Large B-Cell Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
- Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation
- Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
- Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Recurrent Grade 3b Follicular Lymphoma
- Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
- Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
- Recurrent Intravascular Large B-Cell Lymphoma
- Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
- Recurrent Primary Mediastinal Large B-Cell Lymphoma
- Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Recurrent Transformed Non-Hodgkin Lymphoma
- Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
- Refractory ALK-Positive Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
- Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation
- Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
- Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Refractory Grade 3b Follicular Lymphoma
- Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
- Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified
- Refractory Intravascular Large B-Cell Lymphoma
- Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
- Refractory Primary Mediastinal Large B-Cell Lymphoma
- Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Refractory Transformed Non-Hodgkin Lymphoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **BIOLOGICAL:** Chimeric Antigen Receptor T-Cell Therapy
- **PROCEDURE:** Computed Tomography
- **DRUG:** Golcadomide
- **PROCEDURE:** Leukapheresis
- **PROCEDURE:** Positron Emission Tomography
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT06834373
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-02
- **Primary completion:** 2027-03-03
- **Final completion:** 2027-03-03
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06834373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06834373, "Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06834373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*